featured
Outcomes After Cobimetinib Treatment in Rosai–Dorfman Disease Based on MAPK Pathway Alteration Status
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Outcomes After Treatment With Cobimetinib in Patients With Rosai-Dorfman Disease Based on KRAS and MEK Alteration Status
JAMA Oncol 2022 Oct 06;[EPub Ahead of Print], JP Abeykoon, KL Rech, JR Young, A Ravindran, GJ Ruan, S Dasari, DM Morlote, RL King, C Rummage, S Zanwar, AM Acosta-Medina, WO Tobin, MV Shah, NN Bennani, R Vassallo, JH Ryu, MJ Koster, CJ Davidge-Pitts, TE Witzig, G Goyal, RS GoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.